N-acetylcysteine (NAC) may be helpful to reduce drinking and craving in individuals with alcohol use disorder.
This multi-site trial will examine the benefits of NAC on participants' alcohol use, as well as other measures of change in well-being, mood and sleep. It is anticipated that the findings will contribute to evidence for the future use of NAC in the treatment of alcohol use disorder.

For many Australians seeking help for alcohol use (Alcohol Use Disorder or AUD), attempts at recovery are complicated by co-occurring post-traumatic stress disorder (PTSD). New evidence supports integrated treatments, whereby the two problems of PTSD and AUD are treated together at the same time.
This study is investigating whether MDMA-assisted therapy is a safe and effective treatment for the management of both AUD and PTSD. While there is some evidence to show that MDMA-assisted psychotherapy may help reduce PTSD symptoms, there has not been a clinical trial to assess whether MDMA-assisted therapy could be beneficial for people with both PTSD and AUD.

Insomnia is a common co-occurring condition in people with Alcohol Use Disorder (AUD) and presents a challenge for recovery, as each condition can affect and worsen the other.
While treatment options exist to manage AUD and insomnia separately, research is needed to explore integrated treatment options that address both problems at the same time.
This study is investigating whether Suvorexant, a TGA-approved medication for insomnia, is a feasible treatment option for people with co-occurring AUD and insomnia.

This is an observational study investigating relationships between information passively collected via a mobile phone app and changes in alcohol use over 3 months following a supervised alcohol withdrawal program ("detox").
The study seeks to identify factors that may relate to recovery from alcohol dependence and identify possible risk factors associated with returning to use among people who have recently detoxed.

This study will attempt to shed light on the neurocognitive mechanisms behind the cognitive biases that are thought to lead to the development and maintenance of addiction.
Participants will complete cognitive tasks designed to measure cognitive biases while brain activity (EEG), eye movements, skin conductance (GSR), heart rate (ECG) and breathing rate are recorded. The results are expected to provide a more comprehensive understanding of how these biases manifest across the alcohol use spectrum.

This innovative pilot study combines neuroscience, technology and clinical care to explore the use of VR-delivered Approach Bias Modification to retrain the brain’s automatic responses to alcohol-related cues.

Conducted in partnership with Uniting Vic. Tas and St Vincent’s Hospital Melbourne, the trial is currently recruiting inpatients undergoing alcohol withdrawal treatment in order to assess the feasibility, acceptability and potential of this cutting-edge intervention in reducing relapse after people are discharged.

This trial is researching a new brain-training smartphone app that aims to reduce people’s automatic responses to images of alcohol to see if it can help people reduce their alcohol craving and consumption.

The trial has now completed the recruitment phase and is currently analysing the information collected in order to determine whether the brain training can help people who are experiencing alcohol problems and want to reduce or stop drinking.

These trials are examining a new brain-training app that delivers alcohol avoidance training in two different settings.
1. One trial aims to test whether the app can help people in outpatient treatment reduce their alcohol use.
2. The second trial aims to test whether the app can help prevent alcohol relapse among people leaving residential rehabilitation.